Tharimmune Corp (THAR) - מכפיל P/S עתידי
Tharimmune, Inc. (THAR) is mitigating regulatory risks by developing a diversified portfolio of drugs to combat cancer and skin pathologies. The forward price-to-sales ratio visualizes market expectations, where the level captures the current state. The company's ecosystem focuses on pruritus therapy and liver diseases. The business is currently at the start of clinical trials and relies exclusively on venture capital investments.
פילוחי נתונים אנליטיים מרוכזים עבור Tharimmune Corporation (THAR)
The selection of promising issuers is based on comparing market value with expected cash flows using multiples. The forward P/S ratio reflects the relationship between current capitalization and projected revenue; however, for Tharimmune, Inc. (THAR), this calculation is complicated by geopolitical barriers hindering clinical trials and drug certification, making the forward P/S ratio trend a critical indicator of market optimism.
